Mechanical engineering grad David Richardson has received funding for ASU spinout company bioSyntagma, developed while he was a research engineer at the Biodesign Institute. The company’s Light Stream FloCell™ allows researchers to understand how disease-causing cells interact with each other and may be able to answer questions relating to why cancers metastasize, which drugs are most effective for a patient at a given point in time, and what disease mechanisms are active in arthritis, diabetes, and dementia.